Abstract
Reproterol is a synthetic selective beta-adrenoceptor agonist with a xanthine side chain. The bronchial and cardiovascular responses to inhaled reproterol were studied in 14 asthmatics. The study was placebo controlled and double-blind, comparing doubling doses of reproterol from 500 micrograms-8 mg. The peak improvement in FEV1 showed a non-linear dose-response, with an initial plateau at the 1 mg dose producing a mean increase in FEV1 of 17%, but significant further improvement at the 8 mg dose, producing a mean improvement of 29% in FEV1. The time taken for improvement in airways obstruction to start shortened with increasing doses. The duration of bronchodilation was dose-dependent, with the 8 mg dose showing a significantly longer duration of action than the lower doses. The time to drop below 75% of the maximum achieved bronchodilation was 125 min, and was independent of the dose. There were no significant changes in pulse or blood pressure at any dose. The study shows that reproterol is a well tolerated selective beta 2-adrenoceptor agonist whose duration of action and peak effect can be significantly increased by increasing the dose to 8 mg, without producing more unwanted effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Diewitz M. Die Beeinflussung der Reizbildung und Reizleitung sowie der Irritabilität des menschlichen Ventrikels durch das Broncholytikum Reproterol bei Personen mit bradykarden Rhythmusstörungen. Arzneimittelforschung. 1977;27(12):66–72. [PubMed] [Google Scholar]
- Freedman B. J. Trial of a terbutaline aerosol in the treatment of asthma and a comparison of its effects with those of a salbutamol aerosol. Br J Dis Chest. 1972 Jul;66(3):222–229. [PubMed] [Google Scholar]
- Habersang S., Leuschner F., Stroman F., Domenico A., Schlichtegroll A. Pharmakologische Untersuchungen der neuen Substanz Reproterol mit bronchospasmolytischer Wirkung aus der Substanzklasse der beta-Phenyläthyl-aminoalkyl-xanthine. Arzneimittelforschung. 1977;27(12):22–35. [PubMed] [Google Scholar]
- Hetzel M. R., Clark T. J. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax. 1980 Oct;35(10):732–738. doi: 10.1136/thx.35.10.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simonsson B. G., Stiksa J., Ström B. Double-blind trial with increasing doses of salbutamol and terbutaline aerosols in patients with reversible airways obstruction. Acta Med Scand. 1972 Nov;192(5):371–376. doi: 10.1111/j.0954-6820.1972.tb04832.x. [DOI] [PubMed] [Google Scholar]
- Voss H., Aurich R. Bronchospasmolytische Wirkung von Reproterol als Inhalationslösung. Dtsch Med Wochenschr. 1979 Jul 20;104(29):1041–1043. doi: 10.1055/s-0028-1129034. [DOI] [PubMed] [Google Scholar]
- Zecevic D., Tabori D., Mijatovic S., Todic V., Concic B., Aurich R., Stadler R. Effekte des neuen Bronchodilatators Reproterol auf die Herzfunktion bei der Therapie von Asthma bronchiale und chronisch obstruktiver Bronchitis. Arzneimittelforschung. 1977;27(12):53–55. [PubMed] [Google Scholar]